These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35220681)

  • 1. Early termination of pivotal trials in Alzheimer's disease-Preserving optimal value for participants and science.
    Gietl AF; Frisoni GB
    Alzheimers Dement; 2022 Oct; 18(10):1980-1987. PubMed ID: 35220681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
    Clegg A; Bryant J; Nicholson T; McIntyre L; De Broe S; Gerard K; Waugh N
    Health Technol Assess; 2001; 5(1):1-137. PubMed ID: 11262420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's Disease Clinical Trial Research Adaptation Following COVID-19 Pandemic Onset: National Sample of Alzheimer's Clinical Trial Consortium Sites.
    Rhodus EK; Aisen P; Grill JD; Rentz DM; Petersen RC; Sperling RA; Salloway SP; Pierce D; Raman R
    J Prev Alzheimers Dis; 2022; 9(4):665-671. PubMed ID: 36281670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study partners should be required in preclinical Alzheimer's disease trials.
    Grill JD; Karlawish J
    Alzheimers Res Ther; 2017 Dec; 9(1):93. PubMed ID: 29212555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designing Trials of Disease Modifying Agents for Early and Preclinical Alzheimer's Disease Intervention: What Evidence is Meaningful to Patients, Providers, and Payers?
    Messner DA; Rabins P; Downing AC; Irizarry M; Foster NL; Al Naber J; Dabbous O; Fillit H; Gabler S; Krakauer R; Lotz D; Payzant E; Schneider L; Tyrone J; Van Amerongen D; Wuest D
    J Prev Alzheimers Dis; 2019; 6(1):20-26. PubMed ID: 30569082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (4):CD001747. PubMed ID: 11687119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re-Engineering Alzheimer Clinical Trials: Global Alzheimer's Platform Network.
    Cummings J; Aisen P; Barton R; Bork J; Doody R; Dwyer J; Egan JC; Feldman H; Lappin D; Truyen L; Salloway S; Sperling R; Vradenburg G
    J Prev Alzheimers Dis; 2016 Jun; 3(2):114-120. PubMed ID: 28459045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.
    Schneider LS; Mangialasche F; Andreasen N; Feldman H; Giacobini E; Jones R; Mantua V; Mecocci P; Pani L; Winblad B; Kivipelto M
    J Intern Med; 2014 Mar; 275(3):251-83. PubMed ID: 24605808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Bonfill Cosp X; Flicker L
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012216. PubMed ID: 29164603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Facilitators, Challenges, and Messaging Strategies for Hispanic/Latino Populations Participating in Alzheimer's Disease and Related Dementias Clinical Research: A Literature Review.
    Massett HA; Mitchell AK; Alley L; Simoneau E; Burke P; Han SH; Gallop-Goodman G; McGowan M
    J Alzheimers Dis; 2021; 82(1):107-127. PubMed ID: 33998537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selegiline for Alzheimer's disease.
    Birks J; Flicker L
    Cochrane Database Syst Rev; 2003; (1):CD000442. PubMed ID: 12535396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneity of Alzheimer's disease: consequence for drug trials?
    Devi G; Scheltens P
    Alzheimers Res Ther; 2018 Dec; 10(1):122. PubMed ID: 30567585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine for Alzheimer's disease.
    Olin J; Schneider L
    Cochrane Database Syst Rev; 2001; (1):CD001747. PubMed ID: 11279727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
    Truffinet P; Bordet R; Ménard J
    Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).
    Martínez G; Vernooij RW; Fuentes Padilla P; Zamora J; Flicker L; Bonfill Cosp X
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012884. PubMed ID: 29164602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination Therapy for Alzheimer's Disease: Perspectives of the EU/US CTAD Task Force.
    Gauthier S; Alam J; Fillit H; Iwatsubo T; Liu-Seifert H; Sabbagh M; Salloway S; Sampaio C; Sims JR; Sperling B; Sperling R; Welsh-Bohmer KA; Touchon J; Vellas B; Aisen P
    J Prev Alzheimers Dis; 2019; 6(3):164-168. PubMed ID: 31062826
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments in Alzheimer's disease therapeutics.
    Rafii MS; Aisen PS
    BMC Med; 2009 Feb; 7():7. PubMed ID: 19228370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Machine Learning Predictive Models Can Improve Efficacy of Clinical Trials for Alzheimer's Disease.
    Ezzati A; Lipton RB;
    J Alzheimers Dis; 2020; 74(1):55-63. PubMed ID: 31985462
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.